Skip to content

US · PSNL · MEDICAL - DIAGNOSTICS & RESEARCH

Personalis, Inc. (PSNL) intrinsic value and stock valuation

$14.27as of 2026-11-21 · Mkt cap 1.51B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Personalis, Inc. DCF and intrinsic value

InvestorsCraft values PSNL with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from PSNL’s statements →

Personalis, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Fremont, CA 94555 personalis.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$69.7M-2.4% 5y CAGRd
20172025
Net income
-$-81.27M
20172025
Free cash flow
-$-79.45M
20172025
Total equity
$261.2M+6% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$69.7M$84.6M$73.5M$65.1M$85.5M
Operating income-$-88.06M-$-68.27M-$-96.29M-$-115.53M-$-65.35M
Net income-$-81.27M-$-81.28M-$-108.3M-$-113.31M-$-65.23M
EPSd-$-910.69K-$-1.37M-$-2.25M-$-2.48M-$-1.49M
Operating cash flow-$-74.95M-$-45.15M-$-56.26M-$-70.23M-$-70.83M
Capital expenditure-$-4.5M-$-1.6M-$-10.91M-$-49.9M-$-11.08M
Free cash flow-$-79.45M-$-46.75M-$-67.17M-$-120.13M-$-81.91M
Total assets$334.2M$270.3M$225.1M$292.7M$396.5M
Total debt$40M$44.3M$47.7M$48.7M$58.3M
Net debt-$-84.3M-$-47.17M-$-9.26M-$-40.48M-$-47.25M
Total equity$261.2M$203M$129.4M$218.1M$310.3M
Cash and short-term investments$240M$185M$114.2M$167.7M$287.1M
Income statement
20252024202320222021
Revenue$69.7M$84.6M$73.5M$65.1M$85.5M
Cost of revenue$53.9M$57.8M$55.3M$51.7M$53.8M
Gross profit$15.8M$26.8M$18.2M$13.4M$31.7M
Research and development expenses$50.3M$48.9M$64.8M$64.9M$49.3M
Selling, general and administrative expenses$53.6M$46.2M$49.7M$64M$47.7M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$103.8M$95.1M$114.5M$128.9M$97M
Cost and expenses$157.7M$152.9M$169.8M$180.6M$150.9M
Interest income$7.16M$5.51M$5.9M$2.4M$370K
Interest expense$200K$20K$110K$200K$180K
Depreciation and amortization$10.1M$10.9M$11.3M$8.43M$6.01M
Ebitda-$-71M-$-70.3M-$-96.81M-$-104.64M-$-59.01M
Operating income-$-88.06M-$-68.27M-$-96.29M-$-115.53M-$-65.35M
Total other income/expenses, net$6.81M-$-13M-$-11.92M$2.26M$140K
Income before tax-$-81.25M-$-81.27M-$-108.21M-$-113.28M-$-65.21M
Income tax expense$20K$20K$80K$40K$10K
Net income-$-81.27M-$-81.28M-$-108.3M-$-113.31M-$-65.23M
Weighted average shares outstanding$89.2M$59.3M$48.2M$45.7M$43.9M
Weighted average diluted shares outstanding$89.2M$59.3M$48.2M$45.7M$43.9M
Balance sheet
20252024202320222021
Cash and short-term investments$240M$185M$114.2M$167.7M$287.1M
Net receivables$16.2M$8.14M$17.7M$16.6M$18.5M
Inventory$6.14M$3.98M$5.66M$6.38M$4.08M
Total current assets$268M$203M$146.7M$199.7M$318.2M
Property, plant and equipment, net$59.9M$64.7M$75.2M$88.4M$73.5M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$66.2M$67.3M$78.4M$93M$78.3M
Total assets$334.2M$270.3M$225.1M$292.7M$396.5M
Accounts payable$13M$6.4M$14.9M$12.9M$9.22M
Short-term debt$8.08M$9.37M$9.41M$7.61M$5.53M
Deferred revenue$1.56M$3.1M$3.29M$1.29M$4.36M
Total current liabilities$39.6M$31.1M$47.2M$33.1M$31.3M
Long-term debt$31.9M$34.9M$38.3M$41M$52.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$33.4M$36.2M$48.4M$41.4M$54.9M
Capital lease obligations$6.89M$42.6M$46.1M$46.4M$56.5M
Total liabilities$73M$67.3M$95.7M$74.6M$86.2M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-631.26M-$-549.99M-$-468.71M-$-360.41M-$-247.09M
Accumulated other comprehensive income (loss)$100K-$-20K-$-220K-$-910K-$-170K
Total equity$261.2M$203M$129.4M$218.1M$310.3M
Total investments$115.7M$93.6M$57.2M$78.5M$181.5M
Total debt$40M$44.3M$47.7M$48.7M$58.3M
Net debt-$-84.3M-$-47.17M-$-9.26M-$-40.48M-$-47.25M
Cash flow statement
20252024202320222021
Net income-$-81.27M-$-81.28M-$-108.3M-$-113.31M-$-65.23M
Depreciation and amortization$10.1M$10.9M$11.3M$8.43M$6.01M
Stock-based compensation$9.43M$10.7M$14.1M$19.4M$14.4M
Change in working capital-$-10.19M-$-2.59M$13.5M$10.6M-$-31.14M
Accounts receivable-$-8.06M$9.59M-$-1.09M$1.82M-$-12.12M
Inventory-$-200K$4.42M-$-1.93M-$-2.98M$30K
Accounts payable$4.55M-$-8.92M$5.18M$3.09M-$-1.46M
Net cash provided by operating activities-$-74.95M-$-45.15M-$-56.26M-$-70.23M-$-70.83M
Investments in property, plant and equipment-$-4.5M-$-1.6M-$-10.91M-$-49.9M-$-11.08M
Acquisitions, net$0.00$0.00-$-24.01M$0.00$49M
Net cash used for investing activities-$-22.57M-$-35.07M$13.1M$52.5M-$-60.07M
Common stock issued$129.9M$97.8M$3.51M$2.46M$162.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$130.3M$114.7M$11M$1.37M$169.7M
Net change in cash$32.8M$34.4M-$-32.14M-$-16.46M$38.9M
Cash at end of period$126M$93.2M$57M$90.9M$107.4M
Operating cash flow-$-74.95M-$-45.15M-$-56.26M-$-70.23M-$-70.83M
Capital expenditure-$-4.5M-$-1.6M-$-10.91M-$-49.9M-$-11.08M
Free cash flow-$-79.45M-$-46.75M-$-67.17M-$-120.13M-$-81.91M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Personalis, Inc.

        Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.

        CEO
        Christopher Hall
        Employees
        260
        Beta
        2.24

        Explore

        Frequently asked questions

        What is the intrinsic value of Personalis, Inc. (PSNL)?

        Personalis, Inc. (PSNL) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PSNL undervalued?

        PSNL trades at a price of $14.27 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.